Automate Your Wheel Strategy on DXR
With Tiblio's Option Bot, you can configure your own wheel strategy including DXR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DXR
- Rev/Share 0.1555
- Book/Share 7.2539
- PB 1.1843
- Debt/Equity 0.0
- CurrentRatio 0.0
- ROIC 0.0
- MktCap 41555033.0
- FreeCF/Share -0.2829
- PFCF -29.7664
- PE 79.0377
- Debt/Assets 0.0
- DivYield 0
- ROE 0.0157
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Daxor's Innovative ezBVA Lab Service Drives Accessibility and Operational Efficiency Oak Ridge, TN, May 06, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces significant expansion of its blood volume analysis (BVA) capabilities in three new hospitals. This growth is accelerated by the widespread adoption of Daxor's ezBVA Lab service – a cutting-edge, CLIA-certified facility delivering precise, on-demand blood volume analysis results within 24 hours.
Read More
Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Daxor Brings Advanced Blood Volume Analysis Solutions to Elite Heart and Lung Transplantation Forum Oak Ridge, TN, April 22, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, will attend the 45th International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting and Scientific Sessions. This premier event gathers approximately 3,500 international specialists in advanced heart and lung disease treatment for four days of innovative research and knowledge exchange.
Read More
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
Published: March 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 04, 2025 from CEO & President, Michael Feldschuh. Dear Fellow Shareholder: "Behind every overnight success is a decade of relentless work that nobody saw.
Read More
Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Leading Academic Health System Adopts Daxor's Innovative Blood Volume Measurement Capabilities at Two Key Facilities Oak Ridge, TN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the expansion of its blood volume analysis (BVA) at two major hospitals within New Jersey's largest academic health care system. Based on current market momentum and expanding pipeline of opportunities, the Company expects to maintain this accelerated sales trajectory throughout 2025.
Read More
Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Two Groundbreaking Studies on Fluid Management: Pulmonary Artery Pressure Monitoring Falls Short, New Diuretic Insights Emerge Oak Ridge, TN, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces groundbreaking new studies from Duke University Medical Center and Yale School of Medicine, presented at the Technology and Heart Failure Therapeutics Conference (THT). Held from February 11-13, 2025, at the Omni Boston Hotel at the Seaport, the event gathered leading experts in heart failure innovation.
Read More
Daxor to Exhibit at World's Largest Critical Care Conference
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Daxor's Blood Volume Analysis (BVA) Technology Takes Center Stage at SCCM 2025 Oak Ridge, TN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the Society for Critical Care Medicine (SCCM) 2025 Critical Care Congress at the Orange County Convention Center in Orlando, FL from February 23 through February 25, 2025. The Company will be exhibiting at Booth #532.
Read More
Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
Case Reports in the Journal of the American College of Cardiology Underscore the Critical Role of Blood Volume Analysis in Optimizing Heart Failure Treatment Oak Ridge, TN, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a groundbreaking case series published in JACC: Case Reports has identified a distinct phenotype in heart failure patients characterized by expanded blood volume overload and elevated red blood cells, opening new avenues for targeted treatment through therapeutic phlebotomy. In the study, researchers evaluated 179 advanced heart failure patients using Daxor's blood volume analysis …
Read More
New Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Research Published in the Prestigious Journal of Cardiac Failure From Three Institutions Oak Ridge, TN, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a multicenter study published in the prestigious Journal of Cardiac Failure reporting pivotal insights for effective heart failure treatment through the use of Daxor's Blood Volume Analysis (BVA). The study demonstrates how BVA outperforms standard hemodynamic measurements in assessing heart failure volume status, while highlighting its unique capability to detect anemia, a crucial factor for effective treatment.
Read More
About Daxor Corporation (DXR)
- IPO Date 1983-07-25
- Website https://www.daxor.com
- Industry Medical - Instruments & Supplies
- CEO Mr. Michael Richard Feldschuh
- Employees 37